Champignon Brands Appoints Medipharm Labs CEO Pat McCutcheon to Board

This morning Champignon Brands Inc. (CSE: SHRM) announced the appointment of Pat McCutcheon to its board of directors effective immediately. McCutcheon is currently CEO of  MediPharm Labs (TSX: LABS), one of the most respected cannabis operations in Canada. And notably one of the few cash flow generating operators. He founded MediPharm after identifying an important, overlooked segment of the burgeoning cannabis market to create the first pure-play cannabis company focused solely on extraction and API manufacturing.

Prior to founding MediPharm, McCutcheon held senior roles with various large pharmaceutical companies – including Jansen Pharmaceuticals (Johnson & Johnson), Sanofi and Astra Zeneca. During his tenure at Jansen, he was head of the hospital division for renal and mental health products.


Champignon Brands closed yesterday at $1.06, up 381% since first trading March 2, 2020.

FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

San Dimas: First Majestic Silver’s Sleeper Asset

New Gold Q2 Earnings: Record Free Cash Flow

STLLR Gold: The Tower Gold PEA

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Champignon Brands To Acquire Artisan Growers

Champignon Brands (CSE: SHRM) has entered into a definitive agreement to acquire that of Artisan...

Monday, March 16, 2020, 10:18:13 AM

Medipharm Announces White Label Agreement With Argentia Gold

Medipharm Labs (TSX: LABS) and Argentia Gold Corp this morning jointly announced a supply agreement,...

Wednesday, May 27, 2020, 08:34:11 AM

FDA Releases Guidance for Psychedelic Drug Trials With Possibility of Removing Schedule I Classification

The U.S. Food and Drug Administration (FDA) has released a groundbreaking draft guidance to provide...

Tuesday, June 27, 2023, 03:03:00 PM

Canaccord Genuity Raises Medipharm Labs’ Price Target To C$2.50

On Monday Medipharm Labs (TSX: LABS) announced an exclusive medical cannabis partnership with the European...

Tuesday, October 6, 2020, 01:29:18 PM

Medipharm Labs Sees CEO Pat McCutcheon Step Down From Role, Remain As Chairman

Medipharm Labs (TSX: LABS) this morning announced drastic changes to its leadership role, with the...

Thursday, December 10, 2020, 07:38:42 AM